New Step by Step Map For P-gb-IN-1
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Primary trial goals were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polym